Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.
Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.
复制标题
DOI：
10.1158/1535-7163.mct-08-0934
复制
发表时间：
2009-04
影响因子：
5.7
通讯作者：
Gildersleeve JC
中科院分区：
文献类型：
--
作者：
Li Q;Anver MR;Butcher DO;Gildersleeve JC
The tumor-associated Tn antigen has been investigated extensively as a biomarker and therapeutic target. Cancer vaccines containing the Tn antigen as a single tumor antigen or as a component of a polyvalent vaccine have progressed into phase I and phase II clinical trials. One major focus of Tn-based vaccines is the treatment of prostate cancer patients. While expression of the antigen on prostate tumors is a critical prerequisite, previous reports investigating Tn expression in prostate tumors have produced conflicting results. Using a combination of immunohistochemistry and carbohydrate microarray profiling, we show that only 4–26% of prostate tumors express the Tn antigen. Based on our results, the majority of prostate cancer patients do not express the appropriate antigen. Therefore, efforts to pre-select the subset of prostate cancer patients with Tn positive tumors or apply Tn vaccines to other cancers with higher rates of antigen expression could significantly improve clinical response rates. Since conflicting information on carbohydrate expression is a general problem for the field, the approach described in this paper of analyzing antigen expression with multiple antibodies and using carbohydrate microarray profiles to interpret the results will be useful for the development of other carbohydrate-based cancer vaccines and diagnostics.
